Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-870-1 | CAS number: 111-44-4
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
Data source
Reference
- Reference Type:
- other: internet data base
- Title:
- GESTIS Substance database
- Author:
- German Social Accident Insurance
- Year:
- 2 012
- Bibliographic source:
- http://www.dguv.de/ifa/en/gestis/stoffdb/index.jsp
Materials and methods
- Objective of study:
- metabolism
- Principles of method if other than guideline:
- no information
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Bis(2-chloroethyl) ether
- EC Number:
- 203-870-1
- EC Name:
- Bis(2-chloroethyl) ether
- Cas Number:
- 111-44-4
- Molecular formula:
- C4H8Cl2O
- IUPAC Name:
- 1-chloro-2-(2-chloroethoxy)ethane
Constituent 1
- Radiolabelling:
- other: information from radiolabelled material and non-labelled material available.
Results and discussion
Applicant's summary and conclusion
- Executive summary:
The GESTIS database contains following statement indicating that BCEE is metabolized by rats.
In inhalative, oral and intraperitoneal studies on rats, BCEE absorbed was metabolized to the level of 50 - 80 % to form thiodiglycolic acid. Further products (each below 10 % of the total metabolites) were identified: 2-chloroethoxyacetic acid, N-acetyl-S-(2-(2-chloroethoxy)-ethyl)-L-cysteine, 1 -(2-chloroethyl)-beta-D-glucopyranosiduronic acid and S-carboxymethyl-L-cysteine. In an oral study with 14C-labelled BCEE on rats, about 12 % of the radioactivity was exhaled as CO2.
Furthermore, it the database contains following statementes:
Respiratory tract:
Rats exposed to BCEE-vapors in a chamber for 18 h absorbed more than 95 % of the amount, which was calculated for the room to be 75 mg. Although no data is available for humans, effective absorption via the respiratory tract is to be assumed.
Skin:
Apparently, no kinetic studies have been carried out. Based on the high dermal toxicity in tests on rabbits and guinea pigs with the pure grade substance, effective absorbability via intact skin is to be expected. This is also assumed to be true for humans.
Gastrointestinal tract:
Following oral application of 14C-BCEE to rats, about 80 % of the dose was eliminated within 48 hours. From this data, highly effective absorption via the gastrointestinal tract was concluded. Similar results should be expected for humans.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
